Part 1 Basic Information

Name: Xu Ying

Address: School of Pharmacy, Jiangsu University, No. 301 Xuefu Road, Zhenjiang, Jiangsu 212013, China

Tel:0511-85038451 (Optional)

Email: xying@ujs.edu.cn

Part 2 Personal Profile

Dr. Xu is an Associate Professor and Master's Supervisor at the School of Pharmacy, Jiangsu University. The researcher has long been engaged in research and translation/commercialization of new materials and technologies—including nano, biomimetic, controlled-release, targeted, and theranostic technologies—in the fields of pharmaceuticals, food, medical devices, and cosmetics. She has led and participated in multiple national and provincial/ministerial research projects and has published numerous papers in authoritative domestic and international journals, including J. Control. Release, Chem. Eng. J., J. Nanobiotechnology, ACS Appl. Mater. Interfaces, J. Colloid Interface Sci., and Int. J. Nanomedicine. She serves as a young editorial board member of the Journal of Pharmaceutical Research and as a reviewer for journals such as J. Am. Chem. Soc.

Part 3 Education

•2000.9–2004.6, China Pharmaceutical University, Pharmaceutics, Ph.D.

•2004.9—2007.6 China Pharmaceutical University, Pharmaceutics, M.S.

•2000.9—2004.6 China Pharmaceutical University, Pharmaceutics, B.S.

Part 4 Work Experience

•2015.3—2016.3 University of North Carolina at Chapel Hill, Visiting Scholar

•2017.1—2022.9 School of Medicine, Jiangsu University, Postdoctoral Fellow in Clinical Laboratory Diagnostics

•2010.7—Present, School of Pharmacy, Jiangsu University, Associate Professor and Master's Supervisor

Part 5 Research Interests

1.Research on tumor theranostics based on nanotechnology, targeting strategies, and TACE (transarterial chemoembolization)

2.Applications of novel delivery systems in the development of small-molecule drugs, traditional Chinese medicines, and biologics

3.Research and development of novel nanomaterials and hydrogels for pharmaceuticals, medical devices, and cosmetics

Part 6 Research Achievements

6.1 Research Projects

•2019-2022 China Postdoctoral Science Foundation General Program (Special Funding) — Principal Investigator

•2018-2022 China Postdoctoral Science Foundation General Program (First-Class Funding) — Principal Investigator

•2015-2018 National Natural Science Foundation of China (NSFC) Young Scientists Fund — Principal Investigator

•2012-2015 Natural Science Research Project (General Program) for Jiangsu Higher Education Institutions — Principal Investigator

6.2 Publications

1.X Guo, Y Liu, H Zhu, X Yu, F Shi, Q Liu, Q Liu, Y Xu. Aspartic acid reprograms electronic and catalytic pathways of MIL-53(Fe) for neutral-pH cascade glucose sensing [J]. Chem Eng J, 2026, 548: 181842.

2.T Yuan, Z Qi, X Zhang, K, Yang, Y Xu, J Cao. An all-in-one theranostic platform for enhanced TACE: self-developing embolization with dual-targeted arsenic trioxide delivery [J]. J Nanobiotechnology, 2026, 24(1):506.

3.S Li, J Li, W Ren, Y Xu, Q Liu. Schottky-mediated porphyrin-metal-organic framework/Ti3C2-MXene heterojunction for water decontamination via photonic-thermal-enzyme synergistic catalysis [J]. J Colloid Interface Sci. 2025, 691: 137462.

4.F Xiao, B Yan, T Yuan, Y He, X Zhang, X He, W Peng, Y Xu, J Cao. Novel Nanozyme-Based Multicomponent in situ Hydrogels with Antibacterial, Hypoxia-Relieving and Proliferative Properties for Promoting Gastrostomy Tube Tract Maturation [J]. Int J Nanomedicine, 2025,20:827-848.

5.S Huang, S Li, G Li, C Wang, X Guo, J Zhang, J Liu, Y Xu, Y Wang. Fabrication and Characterization of Phyllanthus Emblica Extract-Polyvinyl Alcohol/ Carboxymethyl Cellulose Sodium Antioxidant Hydrogel and Its Application in Wound Healing [J]. Pharmaceutics, 2024, 16, 1531

6.Y Xu, P Chen, L Tang, X Zhang, F Shi, Xg Ning, J Bi, Y Qu, H Liu. Hypoxia responsive and tumor-targeted mixed micelles for enhanced cancer therapy and real-time imaging [J]. Colloids Surf B Biointerfaces, 2022, 215: 112526.

7.Y Qu, Z Wang, M Sun, T Zhao, X Zhu, X Deng, M Zhang, Y Xu, H Liu. A Theranostic Nanocomplex Combining with Magnetic Hyperthermia for Enhanced Accumulation and Efficacy of pH-Triggering Polymeric Cisplatin (IV) Prodrugs [J]. Pharmaceuticals 2022, 15: 480.

8.Y Xu, Y Liu, Q Liu, S Lu, X Chen, W Xu, F Shi. Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy [J]. J Control Release, 2021,10338: 705-718.

9.Y Xu, Y Liu, T He, Y Zhang, M Wang, H Yuan, M Yang. Biguanides decorated albumin nanoparticles loading nintedanib for synergic enhanced hepatocellular carcinoma therapy [J]. Colloids Surf B Biointerfaces. 2021, 207:112020.

10. P Chen, S Lu, B Pan, Y Xu. Development, Optimization, and Pharmacokinetics Study of Bufalin/Nintedanib Co-loaded Modified Albumin Sub-microparticles Fabricated by Coaxial Electrostatic Spray Technology [J]. AAPS PharmSciTech. 2021, 23(1):13.

6.3 Monographs and Textbooks

•Wang Yan (Editor-in-Chief). Pharmaceutics of Traditional Chinese Medicine [M]. Beijing: Chemical Industry Press, 2018. (Editorial Board Member)

6.4 Patents and Software Copyrights

• Xu Ying, Feng Wenxiao, He Taofeng, Liu Hongfei, Lu Shengzhe. A nintedanib self-microemulsifying formulation, soft capsules made therefrom, and preparation method thereof [P], 201710233806.9, Grant Date: 2020-11-20.

• Xu Ying, Tang Lei, Liu Hongfei, Qu Yang, Liu Yulong. Folic acid-nitroimidazole-modified amphiphilic polymer quantum dots, and preparation method and use thereof [P], 201910805488.8, Grant Date: 2022-03-22.

• Xu Ying, Lu Shengzhe, Liu Yulong, Wang Zhen, Liu Hongfei, Tang Lei. Drug-loaded albumin microparticles or nanoparticles and preparation method thereof [P], 201811434742.X, Grant Date: 2022-03-22.